Literature DB >> 31564437

Autosomal-Recessive Mutations in MESD Cause Osteogenesis Imperfecta.

Shahida Moosa1, Guilherme L Yamamoto2, Lutz Garbes3, Katharina Keupp4, Ana Beleza-Meireles5, Carolina Araujo Moreno6, Eugenia Ribeiro Valadares7, Sérgio B de Sousa8, Sofia Maia8, Jorge Saraiva9, Rachel S Honjo10, Chong Ae Kim11, Hamilton Cabral de Menezes12, Ekkehart Lausch13, Pablo Villavicencio Lorini14, Arsonval Lamounier15, Tulio Canella Bezerra Carniero15, Cecilia Giunta16, Marianne Rohrbach16, Marco Janner17, Oliver Semler18, Filippo Beleggia19, Yun Li20, Gökhan Yigit20, Nadine Reintjes3, Janine Altmüller21, Peter Nürnberg21, Denise P Cavalcanti6, Bernhard Zabel22, Matthew L Warman23, Debora R Bertola24, Bernd Wollnik25, Christian Netzer3.   

Abstract

Osteogenesis imperfecta (OI) comprises a genetically heterogeneous group of skeletal fragility diseases. Here, we report on five independent families with a progressively deforming type of OI, in whom we identified four homozygous truncation or frameshift mutations in MESD. Affected individuals had recurrent fractures and at least one had oligodontia. MESD encodes an endoplasmic reticulum (ER) chaperone protein for the canonical Wingless-related integration site (WNT) signaling receptors LRP5 and LRP6. Because complete absence of MESD causes embryonic lethality in mice, we hypothesized that the OI-associated mutations are hypomorphic alleles since these mutations occur downstream of the chaperone activity domain but upstream of ER-retention domain. This would be consistent with the clinical phenotypes of skeletal fragility and oligodontia in persons deficient for LRP5 and LRP6, respectively. When we expressed wild-type (WT) and mutant MESD in HEK293T cells, we detected WT MESD in cell lysate but not in conditioned medium, whereas the converse was true for mutant MESD. We observed that both WT and mutant MESD retained the ability to chaperone LRP5. Thus, OI-associated MESD mutations produce hypomorphic alleles whose failure to remain within the ER significantly reduces but does not completely eliminate LRP5 and LRP6 trafficking. Since these individuals have no eye abnormalities (which occur in individuals completely lacking LRP5) and have neither limb nor brain patterning defects (both of which occur in mice completely lacking LRP6), we infer that bone mass accrual and dental patterning are more sensitive to reduced canonical WNT signaling than are other developmental processes. Biologic agents that can increase LRP5 and LRP6-mediated WNT signaling could benefit individuals with MESD-associated OI.
Copyright © 2019 American Society of Human Genetics. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  MESD; WNT signaling; osteogenesis imperfecta

Mesh:

Substances:

Year:  2019        PMID: 31564437      PMCID: PMC6817720          DOI: 10.1016/j.ajhg.2019.08.008

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  27 in total

1.  Wnt/beta-catenin signaling in mesenchymal progenitors controls osteoblast and chondrocyte differentiation during vertebrate skeletogenesis.

Authors:  Timothy F Day; Xizhi Guo; Lisa Garrett-Beal; Yingzi Yang
Journal:  Dev Cell       Date:  2005-05       Impact factor: 12.270

2.  Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation.

Authors:  Donald A Glass; Peter Bialek; Jong Deok Ahn; Michael Starbuck; Millan S Patel; Hans Clevers; Mark M Taketo; Fanxin Long; Andrew P McMahon; Richard A Lang; Gerard Karsenty
Journal:  Dev Cell       Date:  2005-05       Impact factor: 12.270

3.  Physical localization of the mesoderm development (mesd) functional region.

Authors:  M E Wines; Y Shi; M Lindor; B C Holdener
Journal:  Genomics       Date:  2000-09-15       Impact factor: 5.736

4.  Reversing LRP5-dependent osteoporosis and SOST deficiency-induced sclerosing bone disorders by altering WNT signaling activity.

Authors:  Ming-Kang Chang; Ina Kramer; Hansjoerg Keller; Jonathan H Gooi; Corinne Collett; David Jenkins; Seth A Ettenberg; Feng Cong; Christine Halleux; Michaela Kneissel
Journal:  J Bone Miner Res       Date:  2014-01       Impact factor: 6.741

5.  Mesd binds to mature LDL-receptor-related protein-6 and antagonizes ligand binding.

Authors:  Yonghe Li; Jianglei Chen; Wenyan Lu; Lynn M McCormick; Jianjun Wang; Guojun Bu
Journal:  J Cell Sci       Date:  2005-11-01       Impact factor: 5.285

6.  Two structural and functional domains of MESD required for proper folding and trafficking of LRP5/6.

Authors:  Jianglei Chen; Chia-Chen Liu; Qianqian Li; Christian Nowak; Guojun Bu; Jianjun Wang
Journal:  Structure       Date:  2011-03-09       Impact factor: 5.006

7.  Mutations in WNT1 cause different forms of bone fragility.

Authors:  Katharina Keupp; Filippo Beleggia; Hülya Kayserili; Aileen M Barnes; Magdalena Steiner; Oliver Semler; Björn Fischer; Gökhan Yigit; Claudia Y Janda; Jutta Becker; Stefan Breer; Umut Altunoglu; Johannes Grünhagen; Peter Krawitz; Jochen Hecht; Thorsten Schinke; Elena Makareeva; Ekkehart Lausch; Tufan Cankaya; José A Caparrós-Martín; Pablo Lapunzina; Samia Temtamy; Mona Aglan; Bernhard Zabel; Peer Eysel; Friederike Koerber; Sergey Leikin; K Christopher Garcia; Christian Netzer; Eckhard Schönau; Victor L Ruiz-Perez; Stefan Mundlos; Michael Amling; Uwe Kornak; Joan Marini; Bernd Wollnik
Journal:  Am J Hum Genet       Date:  2013-03-14       Impact factor: 11.025

8.  Requirement for natively unstructured regions of mesoderm development candidate 2 in promoting low-density lipoprotein receptor-related protein 6 maturation.

Authors:  Vidyasagar Koduri; Stephen C Blacklow
Journal:  Biochemistry       Date:  2007-05-09       Impact factor: 3.162

9.  Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture.

Authors:  Karol Estrada; Unnur Styrkarsdottir; Evangelos Evangelou; Yi-Hsiang Hsu; Emma L Duncan; Evangelia E Ntzani; Ling Oei; Omar M E Albagha; Najaf Amin; John P Kemp; Daniel L Koller; Guo Li; Ching-Ti Liu; Ryan L Minster; Alireza Moayyeri; Liesbeth Vandenput; Dana Willner; Su-Mei Xiao; Laura M Yerges-Armstrong; Hou-Feng Zheng; Nerea Alonso; Joel Eriksson; Candace M Kammerer; Stephen K Kaptoge; Paul J Leo; Gudmar Thorleifsson; Scott G Wilson; James F Wilson; Ville Aalto; Markku Alen; Aaron K Aragaki; Thor Aspelund; Jacqueline R Center; Zoe Dailiana; David J Duggan; Melissa Garcia; Natàlia Garcia-Giralt; Sylvie Giroux; Göran Hallmans; Lynne J Hocking; Lise Bjerre Husted; Karen A Jameson; Rita Khusainova; Ghi Su Kim; Charles Kooperberg; Theodora Koromila; Marcin Kruk; Marika Laaksonen; Andrea Z Lacroix; Seung Hun Lee; Ping C Leung; Joshua R Lewis; Laura Masi; Simona Mencej-Bedrac; Tuan V Nguyen; Xavier Nogues; Millan S Patel; Janez Prezelj; Lynda M Rose; Serena Scollen; Kristin Siggeirsdottir; Albert V Smith; Olle Svensson; Stella Trompet; Olivia Trummer; Natasja M van Schoor; Jean Woo; Kun Zhu; Susana Balcells; Maria Luisa Brandi; Brendan M Buckley; Sulin Cheng; Claus Christiansen; Cyrus Cooper; George Dedoussis; Ian Ford; Morten Frost; David Goltzman; Jesús González-Macías; Mika Kähönen; Magnus Karlsson; Elza Khusnutdinova; Jung-Min Koh; Panagoula Kollia; Bente Lomholt Langdahl; William D Leslie; Paul Lips; Östen Ljunggren; Roman S Lorenc; Janja Marc; Dan Mellström; Barbara Obermayer-Pietsch; José M Olmos; Ulrika Pettersson-Kymmer; David M Reid; José A Riancho; Paul M Ridker; François Rousseau; P Eline Slagboom; Nelson L S Tang; Roser Urreizti; Wim Van Hul; Jorma Viikari; María T Zarrabeitia; Yurii S Aulchenko; Martha Castano-Betancourt; Elin Grundberg; Lizbeth Herrera; Thorvaldur Ingvarsson; Hrefna Johannsdottir; Tony Kwan; Rui Li; Robert Luben; Carolina Medina-Gómez; Stefan Th Palsson; Sjur Reppe; Jerome I Rotter; Gunnar Sigurdsson; Joyce B J van Meurs; Dominique Verlaan; Frances M K Williams; Andrew R Wood; Yanhua Zhou; Kaare M Gautvik; Tomi Pastinen; Soumya Raychaudhuri; Jane A Cauley; Daniel I Chasman; Graeme R Clark; Steven R Cummings; Patrick Danoy; Elaine M Dennison; Richard Eastell; John A Eisman; Vilmundur Gudnason; Albert Hofman; Rebecca D Jackson; Graeme Jones; J Wouter Jukema; Kay-Tee Khaw; Terho Lehtimäki; Yongmei Liu; Mattias Lorentzon; Eugene McCloskey; Braxton D Mitchell; Kannabiran Nandakumar; Geoffrey C Nicholson; Ben A Oostra; Munro Peacock; Huibert A P Pols; Richard L Prince; Olli Raitakari; Ian R Reid; John Robbins; Philip N Sambrook; Pak Chung Sham; Alan R Shuldiner; Frances A Tylavsky; Cornelia M van Duijn; Nick J Wareham; L Adrienne Cupples; Michael J Econs; David M Evans; Tamara B Harris; Annie Wai Chee Kung; Bruce M Psaty; Jonathan Reeve; Timothy D Spector; Elizabeth A Streeten; M Carola Zillikens; Unnur Thorsteinsdottir; Claes Ohlsson; David Karasik; J Brent Richards; Matthew A Brown; Kari Stefansson; André G Uitterlinden; Stuart H Ralston; John P A Ioannidis; Douglas P Kiel; Fernando Rivadeneira
Journal:  Nat Genet       Date:  2012-04-15       Impact factor: 38.330

10.  msd is required for mesoderm induction in mice.

Authors:  B C Holdener; C Faust; N S Rosenthal; T Magnuson
Journal:  Development       Date:  1994-05       Impact factor: 6.868

View more
  15 in total

Review 1.  Osteogenesis imperfecta: an update on clinical features and therapies.

Authors:  Ronit Marom; Brien M Rabenhorst; Roy Morello
Journal:  Eur J Endocrinol       Date:  2020-10       Impact factor: 6.664

2.  Patient-reported outcomes in a Chinese cohort of osteogenesis imperfecta unveil psycho-physical stratifications associated with clinical manifestations.

Authors:  Peikai Chen; Zhijia Tan; Anmei Qiu; Shijie Yin; Yapeng Zhou; Zhongxin Dong; Yan Qiu; Jichun Xu; Kangsen Li; Lina Dong; Hiu Tung Shek; Jingwen Liu; Eric H K Yeung; Bo Gao; Kenneth Man Chee Cheung; Michael Kai-Tsun To
Journal:  Orphanet J Rare Dis       Date:  2022-06-28       Impact factor: 4.303

Review 3.  Osteogenesis Imperfecta: Mechanisms and Signaling Pathways Connecting Classical and Rare OI Types.

Authors:  Milena Jovanovic; Gali Guterman-Ram; Joan C Marini
Journal:  Endocr Rev       Date:  2022-01-12       Impact factor: 19.871

4.  Novel mutations in BMP1 result in a patient with autosomal recessive osteogenesis imperfecta.

Authors:  Lei Xi; Shanshan Lv; Hao Zhang; Zhen-Lin Zhang
Journal:  Mol Genet Genomic Med       Date:  2021-04-05       Impact factor: 2.183

Review 5.  Mechanisms of Bone Fragility: From Osteogenesis Imperfecta to Secondary Osteoporosis.

Authors:  Ahmed El-Gazzar; Wolfgang Högler
Journal:  Int J Mol Sci       Date:  2021-01-10       Impact factor: 5.923

Review 6.  Deciphering the Relevance of Bone ECM Signaling.

Authors:  Natividad Alcorta-Sevillano; Iratxe Macías; Arantza Infante; Clara I Rodríguez
Journal:  Cells       Date:  2020-12-07       Impact factor: 6.600

Review 7.  Collagen transport and related pathways in Osteogenesis Imperfecta.

Authors:  Lauria Claeys; Silvia Storoni; Marelise Eekhoff; Mariet Elting; Lisanne Wisse; Gerard Pals; Nathalie Bravenboer; Alessandra Maugeri; Dimitra Micha
Journal:  Hum Genet       Date:  2021-06-24       Impact factor: 4.132

Review 8.  Reproductive options for families at risk of Osteogenesis Imperfecta: a review.

Authors:  Lidiia Zhytnik; Kadri Simm; Andres Salumets; Maire Peters; Aare Märtson; Katre Maasalu
Journal:  Orphanet J Rare Dis       Date:  2020-05-27       Impact factor: 4.123

Review 9.  Osteogenesis imperfecta-pathophysiology and therapeutic options.

Authors:  Julia Etich; Lennart Leßmeier; Mirko Rehberg; Helge Sill; Frank Zaucke; Christian Netzer; Oliver Semler
Journal:  Mol Cell Pediatr       Date:  2020-08-14

10.  The role of WNT1 mutant variant (WNT1c.677C>T ) in osteogenesis imperfecta.

Authors:  Bashan Zhang; Rong Li; Wenfeng Wang; Xueming Zhou; Beijing Luo; Zinian Zhu; Xibo Zhang; Aijiao Ding
Journal:  Ann Hum Genet       Date:  2020-08-05       Impact factor: 1.670

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.